Christopher Bryant

Christopher Bryant has a diverse work experience in the biotechnology and pharmaceutical industries. Christopher currently serves as the Senior Vice President of Technical Operations and Chief Manufacturing Officer at Halozyme Therapeutics, Inc. Prior to that, they worked as the Vice President of Technical Operations at Levo Therapeutics, Inc. and Kastle Therapeutics. Christopher also founded Sagitta Biotherapeutics, a specialty biopharmaceutical company focused on developing glycoprotein therapeutics. Christopher has held various leadership roles at CMC BioConsult, LLC, Vivacelle Bio, Inc., Fresenius Kabi USA, ProMetic BioTherapeutics, Inc., ProMetic Biosciences, and Aventis Behring. Throughout their career, Christopher has gained expertise in technical operations, product development, regulatory strategy, and alliance management.

Christopher Bryant attended the University of Northern Iowa from 1978 to 1982, where they earned a Bachelor of Arts (BA) degree in Chemistry. Subsequently, they pursued higher education at UC San Diego from 1985 to 1990, completing their studies with a Ph.D. in Chemistry.